Core Viewpoint - A class action lawsuit has been filed against Masonite International Corporation (NYSE: DOOR) on behalf of investors who sold shares during the specified Class Period, alleging that the company repurchased its own stock while withholding material non-public information regarding acquisition offers from Owens Corning [1]. Group 1: Lawsuit Details - The lawsuit claims that Masonite repurchased its common stock while in possession of material non-public information, specifically multiple acquisition offers from Owens Corning at prices significantly above the market price [1]. - Investors are encouraged to seek appointment as lead plaintiff representatives by the deadline of April 7, 2026, if they sold Masonite securities during the Class Period from June 5, 2023, to February 8, 2024 [1]. Group 2: Company Overview - Masonite International Corporation is a global building products company based in Tampa, FL, focusing on the design and manufacture of interior and exterior door solutions for residential and commercial construction markets [1].

Core Viewpoint - A class action lawsuit has been filed against BellRing Brands, Inc. (NYSE: BRBR) for investors who acquired securities during the specified class period, highlighting significant stock price drops due to negative financial disclosures [1] Company Overview - BellRing Brands, Inc. is headquartered in St. Louis, MO, and specializes in marketing nutrition products, including ready-to-drink protein shakes, nutrition drinks, powders, and protein bars under the Premier Protein and Dymatize brands [1] Financial Performance - On May 6, 2025, BellRing's CFO indicated that several key retailers reduced their weeks of supply, which is expected to negatively impact third-quarter growth by a mid-single-digit percentage [1] - Following this announcement, BellRing's stock price fell by $14.88 per share, or 19%, from $78.43 on May 5, 2025, to $63.55 on May 6, 2025 [1] - On August 4, 2025, BellRing narrowed its fiscal year 2025 outlook for net sales, attributing the adjustment to competitors gaining market share with a large retailer, leading to a stock price drop of $17.46 per share, or 33%, from $53.64 on August 4, 2025, to $36.18 on August 5, 2025 [1]

Core Viewpoint - A class action lawsuit has been filed against Coupang, Inc. for allegedly misleading investors about its cybersecurity measures, leading to significant financial losses following a major data breach affecting over 33 million customers [1][2][3]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who acquired Coupang securities between May 7, 2025, and December 16, 2025 [1]. - Investors have until February 17, 2026, to seek appointment as lead plaintiff representatives [2]. - The complaint claims that Coupang's inadequate cybersecurity safeguards heightened the risk of a data breach [2]. Group 2: Cybersecurity Incident - In November 2025, disclosures revealed a data breach that compromised sensitive personal information of more than 33 million customers [3]. - Following the breach, Coupang's stock price experienced significant declines, with the company acknowledging the cybersecurity event on December 16, 2025 [3]. - This incident is noted as the largest cybersecurity event in South Korea's history [3].

Core Viewpoint - A class action lawsuit has been filed against Mereo BioPharma Group plc on behalf of investors who purchased Mereo American Depositary Shares during the specified Class Period, alleging misleading information regarding clinical study results [1][3]. Company Overview - Mereo BioPharma Group plc is a biopharmaceutical company headquartered in London, focusing on treatments for rare diseases [2]. Legal Action Details - The lawsuit claims that Mereo misled investors by raising expectations about the ORBIT and COSMIC studies for setrusumab, which did not significantly reduce clinical fracture rates compared to control groups [3]. - Following the disclosure of the study results, Mereo's ADS price fell dramatically from $2.31 on December 26, 2025, to $0.29 on December 29, 2025, resulting in a loss of over 87.7% of its value in one day [3]. Investor Information - Investors who purchased Mereo securities during the Class Period have until April 6, 2026, to seek appointment as a lead plaintiff representative of the class [2].

Core Viewpoint - A class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. on behalf of investors who purchased its common stock during the specified Class Period from August 3, 2023, to December 26, 2025 [1][2]. Company Overview - Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company focused on acquiring and developing novel products for the treatment of rare genetic diseases, headquartered in Novato, California [2]. Lawsuit Details - The lawsuit claims that throughout the Class Period, Ultragenyx made overwhelmingly positive statements regarding the ORBIT and COSMIC Phase 3 clinical trials for setrusumab, intended to treat Osteogenesis Imperfecta [3]. - On December 29, 2025, Ultragenyx disclosed that neither clinical trial achieved its primary endpoint of reducing the annualized clinical fracture rate, resulting in a significant share price drop of over 42%, from $34.19 per share on December 26, 2025, to $19.72 per share on December 29, 2025 [4].

Core Viewpoint - A class action lawsuit has been filed against Klarna Group plc on behalf of investors who acquired Klarna securities during the specified class period, alleging that the company failed to disclose material financial risks related to its IPO [1][3]. Group 1: Lawsuit Details - The lawsuit targets investors who purchased Klarna securities from September 7, 2025, to December 22, 2025, including shares from the September 2025 IPO [1][2]. - Investors have until February 20, 2026, to seek appointment as lead plaintiff representatives of the class [2]. Group 2: Financial Risks and IPO Performance - The lawsuit claims that Klarna's IPO documents did not adequately disclose significant financial risks, particularly the potential for a sharp increase in loss reserves due to the high-risk profiles of its customers [3]. - Following a report on November 18, 2025, indicating that Klarna had set aside more provisions for credit losses than the market expected, the company's share price fell by 21% from the IPO price of $40 to $31.31 [4].

Core Viewpoint - A class action lawsuit has been filed against SLM Corporation (Sallie Mae) for allegedly concealing a significant increase in loan delinquencies during a specific period, leading to investor losses [1][3]. Group 1: Lawsuit Details - The lawsuit represents investors who acquired Sallie Mae securities from July 25, 2025, to August 14, 2025 [1]. - Investors have until February 17, 2026, to seek appointment as lead plaintiff representatives [2]. Group 2: Allegations - The complaint claims that Sallie Mae misled investors about the rising early-stage delinquencies, attributing them to seasonal trends while downplaying the effectiveness of their loss mitigation and loan modification programs [3]. - A report from TD Cowen on August 14, 2025, revealed that July delinquencies increased by 49 basis points month-over-month, which was higher than expected for that season [4]. Group 3: Market Reaction - Following the revelation of the delinquency spike, Sallie Mae's stock price fell by $2.67 per share, or 8.09%, closing at $30.32 on August 15, 2025 [4].

Philadelphia, Pennsylvania--(Newsfile Corp. - February 5, 2026) - National plaintiffs' law firm Berger Montague PC announces that a class action lawsuit has been filed against Mereo BioPharma Group plc (NASDAQ: MREO) ("Mereo" or the "Company") on behalf of investors who purchased American Depositary Shares ("ADS") issued by Mereo during the period from June 5, 2023 through December 26, 2025 (the "Class Period").Investor Deadline: Investors who purchased Mereo securities during the Class Period may, no late ...

Philadelphia, Pennsylvania--(Newsfile Corp. - February 5, 2026) - National plaintiffs' law firm Berger Montague PC announces that a class action lawsuit has been filed against CoreWeave, Inc. (NASDAQ: CRWV) ("CoreWeave" or the "Company") on behalf of investors who purchased or otherwise acquired CoreWeave securities during the period from March 28, 2025 through December 15, 2025 (the "Class Period"), inclusive.Investor Deadline: Investors who purchased CoreWeave securities during the Class Period may, no l ...

Group 1 - A class action lawsuit has been filed against Richtech Robotics Inc. on behalf of investors who purchased securities during the period from January 27, 2026, to January 29, 2026 [1][2] - Richtech Robotics specializes in the design and manufacture of AI-driven service robots for industries such as hospitality, healthcare, and manufacturing [2] - The lawsuit alleges that Richtech falsely characterized its relationship with Microsoft as a "hands-on collaboration" instead of a standard customer relationship, leading to a significant decline in share value when the truth was revealed [3] Group 2 - Investors who purchased Richtech securities during the class period have until April 3, 2026, to seek appointment as lead plaintiff representative [2] - Berger Montague, the law firm handling the case, is recognized for its expertise in complex civil litigation and has recovered over $50 billion for clients over its 55-year history [5]